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INTRODUCTION:  Primary  breast  lymphoma  by  deﬁnition  is  localized  to one  or both  the  breasts  with  or
without  involvement  of regional  lymph  nodes  with  no  other  extra  mammary  site  involvement.  Role of
surgery  in  the treatment  armamentarium  is  less  well  deﬁned.
PRESENTATION  OF  CASE:  A  62  year  old post-menopausal  lady  was  found  to  have  1.2  × 1.2 × 0.6 cm mass
in  the left breast  on  diagnostic  mammography.  Core  needle  biopsy  reveals  marginal  zone  lymphoma.
Complete  staging  work-up  was  performed  which  was  negative  for  regional  spread  and  metastatic  foci.
She was  diagnosed  to have  a localized  stage  IE extra  nodal  low  grade  marginal  zone  lymphoma  of the
MALT  type  involving  breast.  She  received  radiotherapy  to the  breast  and  is  in remission  at follow  up after
one year.
DISCUSSION:  Accurate  diagnosis  requires  adequate  tissue  biopsy  either  by a core  needle  or  a surgical
biopsy  for  histopathologic  evaluation  and  immunophenotyping.  Immunohistochemically  the  tumors  are
positive  for  pan  B-cell  markers  (CD  19, CD  20,  CD22, and  CD  79a)  and lack  T cell markers.  For  stage
IE  Marginal  zone  lymphoma  radiotherapy  alone  and  for stage  IIE  combined  chemo-radiation  offers  the
best possible  control  of  the  disease.  Progression  free  survival  for MZL  is  better  than  diffuse  large  B-cell
lymphoma.
CONCLUSION:  At  present  the best  evidence  support  radiotherapy  in  localized  disease  and combined
chemo-radiation  in  advanced  disease.  Role  of  surgery  is  minimal  and is  seen  in  case  of  diagnostic  dilemma.
Rarity  of  the  diagnosis  precludes  large  scale  prospective  studies  making  therapeutic  decisions  difﬁcult
and  challenging.
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. Introduction
Marginal zone lymphomas are a group of low grade B-cell
ymphomas that arise from the marginal zone of the secondary lym-
hoid follicles. Three distinct subtypes are mentioned in the most
ecent 2008 WHO  classiﬁcation (1) Extra nodal marginal zone or
ALT lymphomas (2) Splenic marginal zone lymphomas (3) Nodal
arginal zone lymphomas [1]. Extra-nodal marginal zone lym-
homa of mucosa-associated lymphoid tissue (MALT) type occurs
ainly in the gastrointestinal tract but can occur in salivary gland,
hyroid, orbit, lung, and breast tissue [2]. Marginal zone lymphomas
f the breast is a rare occurrence. Very sparse literature exists to
escribe the ideal management strategy for these tumors..1. Presentation of case
A 62 year old post-menopausal lady with no signiﬁcant past
edical or family history of breast cancer related malignan-
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cies undergoes a routine screening mammogram which reveals
new onset nodular densities in the left breast as compared to a
normal mammogram a year before (BIRADS 1). Clinical exami-
nation does not reveal any palpable breast lesions and cervical,
axillary or peripheral lymph nodes elsewhere in the body. She
undergoes diagnostic mammography and sonogram which reveals
1.2 × 1.2 × 0.6 cm mass in the left breast. A sonoguided biopsy
demonstrates small lymphocytes with abundant cytoplasm and
the presence of a lympho-epithelial lesion most consistent with a
marginal zone lymphoma.IHC staining was positive for CD20/BCL2
(Fig. 2) and negative for cyclin D1, CD10, CD3 and CD5. MRI  of bilat-
eral breasts did not reveal any mass lesions in the contralateral
breast and is consistent with mammogram ﬁndings (Fig. 1). A com-
plete staging work-up with CT chest, abdomen and pelvis along
with whole body PET-CT was  performed which was negative for
regional spread and metastatic foci. She was diagnosed to have a
localized stage IE extra nodal low grade marginal zone lymphoma
of the MALT type of breast. She is currently undergoing radiother-
apy and is in follow up with oncology and breast clinic and her
disease is in remission on follow up imaging at present.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Panel A: Diagnostic mammogram of left breast cranio-caudal view identiﬁed a new onset dominant mass in the left upper inner quadrant (BI-RADS 4) Panel
B:  short T1 inversion recovery MR images of B/L breast demonstrates suppressed normal breast adiposity in both breasts and a dominant mass with high signal
intensity that corresponds to lymphoma.
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aig. 2. Panel A: H&E sections revealed aggregates of small lymphocytes and few 
anel  B: IHC studies reveal small lymphocytes show predominant staining for CD2
f  lymphocytes.
. Discussion
Primary breast lymphoma by deﬁnition is localized to one or
oth the breasts with or without involvement of regional lymph
odes with no other extra mammary site involvement. Criterion
tandard were deﬁned for primary breast lymphoma by Wiseman
nd laio in 1972 [3] and confer uniformity in diagnosis, evaluation
nd treatment of these tumors. Primary breast lymphomas consti-
ute less than 1% of all NHL, 1.7–2.2% of all extra nodal NHL and
.04–0.5% of all malignant neoplasms of the breast [4,5]. Marginal
one lymphoma constitute approximately 9% of all primary breast
ymphomas [6]. Despite being the second most common variant
f PBL it is exceedingly rare in occurrence. In the largest multi-
enter retrospective study (1980–2003) only 24 cases of marginal
one lymphoma were reported [6]. A pathophysiological role of an
nciting chronic inﬂammation or infection like the gastrointestinal
ALT lymphomas is not described in breast tissue (Fig. 2).
An enlarging painless breast mass in an elderly patient is the
ost common presentation. Bilateral presentation is not uncom-
on. The median age at presentation is 68 years (47–92 yrs)
ith a higher female predilection. They tend to be larger than
pithelial breast cancers, and the average size is 3 cm.  Marginal
one lymphomas tend to be low grade tumors with relative
bsence of advanced disease like respiratory symptoms, bulky lym-red large lymphoid cells. A few distorted reactive lymphoid follicles also appear.
2 and negative for CD33/CD5/CD10 and cyclinD1. Overall Ki-67 stains approx. 10%
phadenopathy, “B” symptoms, and central nervous system (CNS)
symptoms [6–8]. Most common mammographic features are soli-
tary, uncalciﬁed soft-tissue mass seen in 60–70% of the patients
[9]. Sonographic appearance is not speciﬁc for any lymphoma.
Well deﬁned to poorly deﬁned, hypo- to hyperechoic masses and
focal or diffuse involvement with variable attenuation are the
main ultrasonographic features [9]. The typical appearance on an
MRI  is an ill-deﬁned, non-spiculated, hypointense masses in T1W
images, which showed rapid and strong enhancement in dynamic
sequence. Non-invasive studies are in agreement with ﬁnal patho-
logical diagnosis nearly 93% of the time [9].
Diagnosis of marginal zone lymphoma is based on cyto-
logical and histopathologic features. Fine needle as piration
cytology alone is an inadequate study for primary breast lym-
phoma. Often it becomes difﬁcult to distinguish lymphoid cells
from reactive lymphocytes. Adequate tissue biopsy either by
a core needle or a surgical biopsy for histopathologic eval-
uation and immunophenotyping is of paramount importance.
Centrocyte (small to medium size lymphocyte with abundant
cytoplasm and irregularly shaped nuclei) inﬁltration, scattered
blast cells and lymph-epithelial lesion are pathognomonic of
marginal zone lymphoma regardless of the site of origin. Immuno-
histochemically the tumors are positive for pan B-cell markers
(CD 19, CD 20, CD22, and CD 79a) and lack staining for T
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ell markers CD5, CD10 and Bcl-1. Clonality and tumorigenesis
f marginal zone lymphomas are determined by chromosomal
ranslocations. The translocation t (11; 18) (q21; q21) is found
n most anatomical sites and is seen in nearly 50% of the cases.
ranslocation t(11:18) (q21;q21) is next most common seen in 20%
f marginal zone lymphomas but not speciﬁc as there is signiﬁcant
verlap from follicular lymphoma subtype. Chromosomal translo-
ations t(1:14) (p22;q32) is rare however more speciﬁc for marginal
one lymphoma of the GI tract [2,10,11].
Staging work-up recommended by NCCN for extranodal NHL is
o different for any subtype of primary breast lymphomas. At the
inimum a careful history and physical, CT chest, abdomen and
elvis, or integrated PET-CT, Bone marrow aspiration and biopsy,
nd laboratory studies (CBC, Comprehensive metabolic panel) are
ecommended. Assessment of the contralateral breast is essen-
ial since 10% of the lymphomas involve the contralateral breast
12]. Luganos modiﬁcation of the Ann arbor staging system is used
o determine the stage of the extra-nodal lymphoma. Stage IE
eﬁnes disease limited to breast only and stage IIE involves lesion
imited to the breast and ipsilateral lymph nodes. Disease that
as metachronous spread beyond the breast with primary breast
resentation including bone marrow is included in IIE by expert
roups.
Treatement options in primary breast lymphoma are tailored
ccording to the biological behavior of the lymphoma. For aggres-
ive variants like diffuse large B-cell lymphoma systemic therapy
chemotherapy) alone or combined with some kind of local ther-
py (Radiotherapy or surgery) offers the best survival rates [13].
owever for indolent and low grade lymphomas local treatment
radiotherapy or surgery) would sufﬁce. Selection of treatment
or marginal zone lymphoma varied widely in literature. In the
argest reported IELSG series radiotherapy and surgery either alone
r in combination were used in the treatment of nearly 70% of
he reported series. Chemotherapy alone or in combination was
sed in less than 25% of patients. Role of surgery in the treat-
ent of marginal zone lymphoma and lymphomas overall has
eclined since 1990. Majority of the surgical series with a lumpec-
omy or quadrentectomy included patients with a pre-operative
reast lesion misdiagnosed as a poorly differentiated carcinoma
r for obtaining a tissue diagnosis. Outside of these two  indica-
ions radical surgery is met  with inferior survival rates and offers
o real advantage [6,13]. Thus for a localized stage IE Marginal zone
ymphoma radiotherapy alone and for an advanced lesion stage IIE
involved lymph nodes or discontiguous spread) combined chemo-
adiation offers the best possible control of the disease. Prognosis
or MZL  is comparatively better than Aggressive lymphomas like
LBCL and follicular lymphomas. Progression free survival for MZL
f the breast was 72% at 3 years,56% at 5 years and 34% at 10 years,
espectively (log-rank test:P = 0.55). The median PFS was 7.3years
n MZL.OS for MZL  was 100% at 3 years, 92% at 5 years and 64% at
0 years, respectively (log-rank test = 0.04) [6].
. Conclusion
Marginal zone lymphoma is considered as an indolent lym-
homa of the breast. Epidemiological surveys describing clinical
eatures and out-comes do not exist. Principles of diagnosis and
taging are no different from lymphomas at other sites. At present
est evidence support radiotherapy in localized disease and com-
ined chemo-radiation in advanced disease. Rarity of the diagnosis
recludes large scale prospective studies making therapeutic deci-
ions difﬁcult and challenging.
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